Novartis has decided to terminate the ALTITUDE study evaluating the potential benefits of Rasilez/Tekturna (aliskiren) in reduction of risk of cardiovascular and renal events in patients with type 2 diabetes and renal impairment...
JDRF announced it will support a pioneering diabetes research program that is developing a first-of-its-kind cell therapy for type 1 diabetes and other forms of insulin-dependent diabetes. The therapy is a combination product that packages immature cells made from human embryonic stem cells (hESCs) that over time develop into mature pancreatic hormone producing cells...
JDRF-funded researchers have begun enrolling adult patients with type 1 diabetes in the REMOVAL study, to test whether metformin-a drug commonly used to treat type 2 diabetes-could help prevent or reduce the risk of cardiovascular complications in people with type 1 diabetes...
A study released by Novo Nordisk at the International Diabetes Federation (IDF) 21st World Diabetes Congress in Dubai has found that the combination insulin degludec/insulin aspart, currently being developed, significantly reduced hypoglycemia in type 1 diabetes and type 2 diabetes patients...
Sanofi announced positive results from the Gel Duo 1 study of it's investigational GLP-1 agonist, Lyxumia (lixisenatide) in the treatment of type 2 diabetes patients. The results show that patients with type 2 diabetes uncontrolled on oral anti-diabetics (OADs) – mainly metformin - significantly reduced their HbA1c levels when...
Data from the A1chieve® study, evaluating adverse events and effectiveness of Novo Nordisk insulins (NovoMix 30, Levemir and NovoRapid) in 66,726 people with type 2 diabetes, shows that type 2 diabetes patients can significantly improve their blood glucose control with a low occurrence of low blood sugar (hypoglycemia)...
JDRF has partnered with over 700 online stores to raise money for diabetes research. To participate in this fundraiser all you have to do is download the JDRF toolbar, visit the sites of participating merchants, and shop. Every time you make a purchase, JDRF will receive 1%-5% of the price. Not only will the the cost of your purchases not go up, but you'll also be eligible to receive special offers.
Researchers at Joslin Diabetes Center have determined key differences between Type 1 and Type 2 diabetes in the Asian American population. This study, published today in PLoS ONE, identified ways to differentiate the types of diabetes, which can be clinically similar in young Asian Americans.
Eli Lilly has announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles (MOSA1c study) that people with type 2 diabetes face which prevent them from reaching their ultimate treatment goals...
The U.S. Food and Drug Administration (FDA) issued draft guidance designed to help investigators and manufacturers as they develop and seek approval for artificial pancreas device systems to treat type 1 diabetes. This step comes after a large campaign led by the Juvenile Diabetes research Foundation ...